TrialJournal of Crohn's & colitis2020

Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis.

Séverine Vermeire et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.